Loading...
Market
Will FTC impose conditions on Novo Nordisk's acquisition of Catalent by Q1 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official FTC announcements or press releases detailing conditions
Story
Senator Warren Urges FTC to Scrutinize Novo Nordisk's $16.5 Billion Catalent ($CTLT) Deal
Oct 10, 2024, 04:05 PM
US Senator Elizabeth Warren has called for regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's parent foundation would acquire Catalent ($CTLT), a contract drug manufacturer. Warren urged the Federal Trade Commission (FTC) to investigate whether the deal would give Novo Nordisk ($NVO) an unfair advantage in the market for obesity and diabetes drugs. She expressed concerns about the potential control Novo Nordisk would gain over some of Catalent's plants.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
FTC files lawsuit • 25%
FTC issues warning • 25%
FTC takes no action • 25%
FTC reaches settlement • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
